PHILADELPHIA, Nov. 2 /PRNewswire/ -- Sanofi Pasteur, the vaccines division of sanofi-aventis Group , presented Safety of a Quadrivalent (A,C,Y,W-135) Meningococcal Vaccine When Given to Infants with Other Pediatric Vaccines at the 47th Annual Meeting of the Infectious Diseases Society of America (IDSA) this past weekend. The annual meeting of physicians, scientists, and other health-care professionals who specialize in infectious diseases was held from October 29 through November 1 in Philadelphia, PA.
“The investigators concluded that the two-dose Menactra vaccine was generally well-tolerated by the infants in the study,” said Miriam Pina, M.D., Sanofi Pasteur’s clinical director who presented the data at IDSA. According to Pina, the most common side effects experienced in this study were minor and short-term, including injection site pain, redness, swelling and irritability.
Menactra (Meningococcal [Groups A, C, Y and W-135] Polysaccharide Diphtheria Toxoid Conjugate Vaccine) is the only licensed conjugate vaccine in the U.S. for persons 2 through 55 years of age for active immunization against invasive meningococcal disease caused by N meningitidis serogroups A, C, Y, and W-135. Since it was first licensed in the U.S. by the Food & Drug Administration in 2005, more than 28 million doses of Menactra vaccine have been distributed.
For more information about Menactra vaccine, talk to your health-care professional or go to www.menactra.com.
Sanofi-aventis, a leading global pharmaceutical company, discovers, develops and distributes therapeutic solutions to improve the lives of everyone. Sanofi-aventis is listed in Paris and in New York .
Forward Looking Statements
CONTACT: Susan Watkins, +1-570-957-2563, susan.watkins@sanofipasteur.com
Web site: http://www.sanofipasteur.com/
